Rare disease Background:
Background
Systemic lupus erythematosus (SLE) is a complex inflammatory disease with an average prevalence of about 50 case per 100 000 individuals [1] . Ocular manifestations of SLE were first described in 1929 by Semon and Wolff; incidences are not infrequent, occurring in up to one-third of patients [2, 3] . The thrombotic and inflammatory nature of the disease can affect almost every anatomical structure of the eye. Symptoms range from dry eyes as seen in keratoconjunctivitis sicca posttransplantation, also known as secondary Sjogren's Syndrome, to complete vision loss in diseases that affect the retina and optic nerve. Optic nerve disease, represented by optic neuritis and ischemic optic neuropathy (anterior and posterior) are rare, but more severe, vision-threatening manifestations that affect only 1% of SLE patients [4] . In this report, we describe a patient with SLE who presented with optic neuropathy, and we review the literature associated with clinical and serologic diagnosis as well as acute and chronic management.
Case Report
A 44-year-old African-American female with what was reported to be stable SLE, end stage renal disease secondary to lupus nephritis, and a failed renal transplant, developed photophobia and fatigue followed by 4 days of painless, acute vision loss in the right eye. She denied headache, skin rash, joint pains, chest pain, or any other constitutional symptoms.
Physical examination revealed no skin rash, normal cardiac and lung auscultation, and a normal abdominal examination. Neurological examination revealed normal strength and sensation in the upper and lower extremities and cranial nerves I and III-XI were grossly intact. Ophthalmologic examination revealed that she was unable to perceive light (NLP) with the right eye and the visual acuity of her left eye measured 20/25. Near vision without correction was nil on the right and a brisk Jaeger 1 on the left. Color vision was nil on the right and she was able to identify 10 out of 10 Hardy-Rand-Rittler plates on the left. Visual fields to confrontation on the right side revealed that the patient could see hand motion in her temporal field only. Visual fields were full to confrontation on the left side. Pupils were 3 mm being nonreactive on the right and 1+ reactive on the left and there was a 2+ right relative afferent pupillary defect evident. The patient was orthophoric at distance with full ductions, versions, pursuit, and saccadic eye movements. There was no significant ptosis, enhanced ptosis, lid lag, or lid retraction noted. Cranial nerves V and VII were intact including normal corneal reflexes. Ocular tensions were 12 and 17, respectively. Slit lamp examination was essentially normal each eye. Fundoscopic examination revealed marked optic disc swelling with a markedly diffusely pale optic disc and 1+ retinal venous tortuosity (Figure 1 ). There were no vitreous cells and no papillary or retinal hemorrhages. The examination of left eye, including the optic disc and retinal vasculature, was normal. Differential diagnosis included acute ischemic optic neuropathy, viral neuroretinitis, compressive neoplasm or abscess, and toxic drug effect.
Computerized tomography (CT) scan of the head showed no neoplastic masses or signs of acute infection/brain abscess. CT scan of the orbits showed no compressive lesion of the optic nerve. There were no clinical or historical signs of systemic infection and infectious laboratory workup was overall negative. Drug screening and serum electrolytes were within normal limits. Inflammatory laboratory testing revealed elevated titers of several inflammatory markers consistent with a SLE flare: erythrocyte sedimentation rate (61 mm/hour; normal: 0-29 mm/hour); anti-nuclear antibody (>12 U; normal: <1 U); anti-ds-DNA antibody (294 IU/mL; normal: <30 IU/mL); antiSm antibody (>8 U; normal: <1 U); and anti-phospholipid IgG antibody (20.9 GPL; normal <10 GPL). Complement (C3 and C4) levels were within normal reference ranges. Acute optic neuropathy was diagnosed on the basis of the clinical examination and the unusual severity of the vision loss (NLP), coupled with the serologic evidence of a SLE flare. Treatment with high-dose intravenous dexamethasone (250 mg every 6 hours) was initiated and vision in the right eye began to return within the first few hours. Intravenous dexamethasone was continued for 3 days and her vision improved to the point that she could make out a hand moving 2 feet in front of her in all visual fields. She was transitioned to oral prednisone (80 mg/day) which was subsequently tapered over 3 weeks. Unfortunately, vision in her right eye failed to completely return, and at a 
Discussion
The pathogenesis of SLE is complex and can be comprised of multiple factors including gender and environment [5] . These factors can lead to the formation of both antibodies and immune complexes which can lead to a systemic, global inflammatory reaction. It is this global inflammation that leads to the multiple organ changes seen in SLE. Clinical history and examination involve confirming 4 out of 11 of the diagnostic criteria for SLE developed by the American College of Rheumatology [6, 7] . These findings include malar rash, discoid rash, photosensitivity, oral ulcers, non-erosive arthritis of 2 or more peripheral joints, pleuritis or pericarditis, a renal disorder involving persistent proteinuria or cellular casts, a neurologic disorder involving seizures or psychosis, a hematologic disorder involving either hemolytic anemia, leukopenia, lymphopenia, or thrombocytopenia, an immunologic disorder involving anti-DNA antibody, Anti-Sm antibody or positive finding of antiphospholipid antibodies, and a positive antinuclear antibody. These findings may be noted on the present history and physical or documented at some time in the past.
Once SLE is confirmed, a thorough ophthalmologic examination must be conducted. Many different ocular findings may be present in SLE including eyelid abnormalities, ocular adnexa, keratoconjunctivitis sicca, iridocyclitis, retinal vasculitis, vasoocclusive disease, choroidopathy, and optic neuropathy [3] . Fundoscopic examination looking at blood vessels and nerves in detail is crucial in order to not overlook pathology (Table 1) .
SLE-associated optic neuritis characteristically presents as an acute, painful loss of vision secondary to infarction of the optic nerve secondary to arteriolar fibrinoid necrosis [8] . Conversely, optic neuropathy associated with SLE presents as bilateral, painless vision loss, with or without optic disc swelling; it is secondary to an ischemic process affecting the optic nerve head and retrobulbar nerve [3, 8] . In a rare cohort of patients, unilateral vision loss associated with ischemic optic neuropathy is observed in patients with the presence of antiphospholipid antibodies; visual loss is secondary to a focal thrombotic event affecting the microcirculation rather than a global, vasculitic process [9] . Our patient presented with unilateral, painless vision loss, and swelling of the optic disc in the setting of elevated antiphospholipid antibody titers in a patient with an active SLE flare.
When SLE-associated optic neuritis is suspected, advance testing may include fundus fluorescein angiography (FFA), a complementary test that can detect retinal vasculature changes [4] . FFA in optic neuritis usually reveals vasodilation of the peripapillar capillaries and hyperfluorescence during the late phases of the examination [10] . Ischemic optic neuropathies are characterized by incomplete capillary and choroidal filling, followed by hyperfluoresceinic leakage (Figure 2 ). Optic neuropathies cause by retrobulbar lesions can have a normal funduscopic examination and FFA. In these cases, a magnetic resonance imaging (MRI) with gadolinium contrast may be needed in order to diagnose optic nerve enlargement and enhancement [4, 11] .
Immunosuppressive therapy is the mainstay treatment for both systemic and ocular SLE [12] . Treatment for ischemic optic neuropathy is controversial, especially in the presence of antiphospholipid antibodies. Because an acute thrombotic event rather than a global vasculitis appears to be the mechanism leading to visual loss, anticoagulation with warfarin or aspirin should be considered [12, 13] . Although high-dose corticosteroids are usually given as empiric therapy, their role is to treat the accompanying systemic autoimmune illness rather than thrombotic sequelae from antiphospholipid syndrome [13] . Although methylprednisolone is the standard steroid given in cases of optic neuritis, we chose to use dexamethasone as it is known to have a better central nervous system (CNS) penetration. This higher CNS penetration is due to its ability to achieve higher free plasma levels related to its protein-binding capacity [14] . Hydroxychloroquine appears to be protective against thrombosis in patients with SLE and is considered as an approach to prevent thrombosis in the presence of antiphospholipid antibodies [15] . The standard treatment for SLE optic neuropathy includes high-dose intravenous methylprednisolone (1 g/day for 3 days) followed by oral prednisone (1 mg/kg/day) [16] . Unfortunately, up to 29% of patients may be refractory to corticosteroids [17] . Pulse-dosed intravenous cyclophosphamide for 6 months has been studied in open and controlled clinical trials and seems to be effective in corticosteroid refractory optic neuropathy [18] .
Conclusions
Although rare, optic neuritis and ischemic optic neuropathy are ophthalmologic complications of SLE which can present suddenly and cause permanent vision loss. Obtaining a good patient history and performing a thorough funduscopic examination are crucial in making the proper diagnosis. Unilateral optic neuropathy with anti-phospholipid antibodies deserves early high-dose IV corticosteroids followed by a taper in order to treat the inflammatory component of SLE. Anticoagulation and hydroxychloroquine should strongly be considered as they may protect against additional thrombotic events. Physicians' understanding of this workup and treatment may prevent vision loss in their SLE patients.
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